<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017935</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-0932</org_study_id>
    <nct_id>NCT05017935</nct_id>
  </id_info>
  <brief_title>RADIANCE TRIO Continued Access Protocol</brief_title>
  <acronym>TRIO CAP</acronym>
  <official_title>RADIANCE TRIO Continued Access Protocol (TRIO CAP): A Study of the ReCor Medical Paradise System in Clinical Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReCor Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReCor Medical, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TRIO CAP is a non-randomized study designed to allow for continued access to ultrasound renal&#xD;
      denervation therapy via the Paradise System, and to allow for the on-going collection of&#xD;
      safety and effectiveness data in subjects with uncontrolled hypertension despite the&#xD;
      prescription of three or more antihypertensive medications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>From baseline to 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in average daytime ambulatory systolic BP</measure>
    <time_frame>From baseline to 2 months post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in average 24-hr/night-time ambulatory systolic BP</measure>
    <time_frame>From baseline to 2 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average daytime/24-hr/night-time ambulatory systolic BP</measure>
    <time_frame>From Baseline to Months 6 and 12 post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average office systolic/diastolic BP</measure>
    <time_frame>From Baseline to Months 2, 6, 12, 24, 36, 48, and 60 post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average home systolic/diastolic BP</measure>
    <time_frame>From Baseline to Months 2, 6, 12, 24, 36, 48, and 60 post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average 24-hr/night-time ambulatory diastolic BP</measure>
    <time_frame>From baseline to Months 2, 6, and 12 post procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hypertension</condition>
  <condition>Hypertension, Resistant to Conventional Therapy</condition>
  <condition>Vascular Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Renal Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <description>Renal angiogram and renal denervation (Paradise Renal Denervation System)</description>
    <arm_group_label>Renal Denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Average office BP ≥140/90 mmHg at screening visit despite taking stables doses of&#xD;
             three or more antihypertensive medications, including a diuretic, for at least 4 weeks&#xD;
             prior to consent&#xD;
&#xD;
          -  Documented daytime ABP ≥135/85 mmHg following 4 week stabilization period on on&#xD;
             standardized antihypertensive medication regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal artery anatomy ineligible for treatment&#xD;
&#xD;
          -  Secondary hypertension not including sleep apnea&#xD;
&#xD;
          -  Type I diabetes mellitus or uncontrolled Type II diabetes (defined as plasma HbA1c&#xD;
             ≥9.0%)&#xD;
&#xD;
          -  eGFR &lt;40&#xD;
&#xD;
          -  Brachial circumference ≥42 cm&#xD;
&#xD;
          -  Any history of cerebrovascular event or severe cardiovascular event within 3 months&#xD;
             prior to consent&#xD;
&#xD;
          -  Documented repeat (&gt;1) hospitalization for hypertensive crisis within 3 months prior&#xD;
             to consent&#xD;
&#xD;
          -  Documented confirmed episode(s) of unstable angina within 3 months prior to consent&#xD;
&#xD;
          -  Chronic oxygen support or mechanical ventilation other than nocturnal respiratory&#xD;
             support for sleep apnea&#xD;
&#xD;
          -  Primary pulmonary hypertension&#xD;
&#xD;
          -  Night shift workers&#xD;
&#xD;
          -  Pregnant, nursing or planning to become pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Fisher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital/Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ajay Kirtane, MD, SM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Medical Center/New York-Presbyterian Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Reeve-Stoffer, PhD</last_name>
    <phone>+44 7947 748006</phone>
    <email>hreeve-stoffer@recormedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Sheehan, MLIS</last_name>
    <email>liz.sheehan@recormedical.com</email>
  </overall_contact_backup>
  <link>
    <url>https://www.recormedical.com/</url>
    <description>ReCor Medical company website</description>
  </link>
  <reference>
    <citation>Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A, Basile J, Bloch MJ, Daemen J, Lobo MD, Mahfoud F, Schmieder RE, Sharp ASP, Weber MA, Sapoval M, Fong P, Pathak A, Lantelme P, Hsi D, Bangalore S, Witkowski A, Weil J, Kably B, Barman NC, Reeve-Stoffer H, Coleman L, McClure CK, Kirtane AJ; RADIANCE-HTN investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021 Jun 26;397(10293):2476-2486. doi: 10.1016/S0140-6736(21)00788-1. Epub 2021 May 16.</citation>
    <PMID>34010611</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Pressure</keyword>
  <keyword>Uncontrolled Hypertension</keyword>
  <keyword>Essential Hypertension</keyword>
  <keyword>Resistant Hypertension</keyword>
  <keyword>Denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

